Ligand Pharmaceuticals Incorporated
$ 196.17
2.50%
26 Feb - close price
- Market Cap 3,766,884,000 USD
- Current Price $ 196.17
- High / Low $ 199.06 / 178.72
- Stock P/E 83.94
- Book Value 48.34
- EPS 2.28
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.05 %
- 52 Week High 212.49
- 52 Week Low 93.58
About
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Analyst Target Price
$244.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-08 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 | 2023-08-08 | 2023-05-04 | 2023-02-22 |
| Reported EPS | 3.09 | 0.24 | 1.33 | 1.27 | 1.84 | 1.4 | 1.2 | 1.38 | 1.02 | 1.42 | 2.28 | 1.36 |
| Estimated EPS | 1.93 | 1.43 | 0.78 | 1.1901 | 1.35 | 1.06 | 0.78 | 0.66 | 0.61 | 0.64 | 0.89 | 1.19 |
| Surprise | 1.16 | -1.19 | 0.55 | 0.0799 | 0.49 | 0.34 | 0.42 | 0.72 | 0.41 | 0.78 | 1.39 | 0.17 |
| Surprise Percentage | 60.1036% | -83.2168% | 70.5128% | 6.7137% | 36.2963% | 32.0755% | 53.8462% | 109.0909% | 67.2131% | 121.875% | 156.1798% | 14.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.63 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.08 | $2.5 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LGND
2026-02-19 22:52:02
Aberdeen Group plc reduced its stake in Ligand Pharmaceuticals by 17.2% in Q3, owning 189,748 shares valued at $33.61 million. Institutional investors collectively own 91.28% of the stock, while company insiders have sold 3,205 shares worth $611,192 in the last quarter. Analysts maintain a "Moderate Buy" consensus with an average price target of $239.33.
2026-02-13 03:27:43
Ligand Pharmaceuticals (LGND) will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on supporting the development of medicines through financing and licensing technologies, partnering with leading pharmaceutical companies, and leveraging its Captisol® and NITRICIL™ platform technologies. The article also provides detailed information on insider trading activity, institutional holdings, analyst ratings, and price targets for LGND.
2026-02-11 09:58:12
Impax Asset Management Group plc has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 23.1%, selling 60,000 shares but still retaining over 200,000 shares valued at approximately $35.5 million. Analyst sentiment for LGND is positive, with a "Moderate Buy" consensus rating and a target price significantly above its current trading price. However, company insiders have been engaged in selling shares, indicating some internal divestment.
2026-02-03 02:28:23
Villere ST Denis J & Co. LLC has reduced its stake in Ligand Pharmaceuticals Incorporated by 2.5%, now holding 279,950 shares valued at $49.59 million, representing 1.43% of the company. Despite this reduction, Ligand Pharmaceuticals remains Villere ST Denis J & Co. LLC's second-largest holding, accounting for 4.8% of its portfolio. The biotechnology company has received a "Moderate Buy" consensus rating from analysts, with an average price target of $239.33, and reported strong Q3 earnings with $3.09 EPS and 123% YoY revenue growth.
2026-01-18 06:28:11
Stephens Investment Management Group LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 8.3% in the third quarter, selling over 50,000 shares. Despite this, the firm still holds a significant position worth approximately $98.23 million. Ligand Pharmaceuticals reported strong earnings and revenue, with positive analyst sentiment, maintaining a "Moderate Buy" rating and a consensus price target indicating potential upside.
2026-01-09 16:31:21
Over the past year, insiders at Ligand Pharmaceuticals (NASDAQ:LGND) sold US$2.8 million worth of stock, while purchasing US$1.2 million. This significant selling, particularly by Independent Director Jason Aryeh at a price below the current valuation and recent sales by CFO Octavio Espinoza, suggests a cautious outlook from insiders. Despite insiders holding 2.1% of the company, the net selling activities raise questions for potential investors.
